Similar articles for PMID: 24665085

Year	Number of Results
1988	1
1989	2
1995	1
1997	2
1998	2
2002	1
2004	5
2006	2
2007	4
2008	5
2009	5
2010	7
2011	13
2012	12
2013	18
2014	8
2015	13
2016	14
2017	18
2018	13
2019	9
2020	17
2021	12
2022	15
2023	5
2024	0

1

First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule.

Sörensen J, Sandberg D, Sandström M, Wennborg A, Feldwisch J, Tolmachev V, Åström G, Lubberink M, Garske-Román U, Carlsson J, Lindman H. Sörensen J, et al. J Nucl Med. 2014 May;55(5):730-5. doi: 10.2967/jnumed.113.131243. Epub 2014 Mar 24. J Nucl Med. 2014. PMID: 24665085 Free article. Clinical Trial.

2

Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT.

Sörensen J, Velikyan I, Sandberg D, Wennborg A, Feldwisch J, Tolmachev V, Orlova A, Sandström M, Lubberink M, Olofsson H, Carlsson J, Lindman H. Sörensen J, et al. Theranostics. 2016 Jan 1;6(2):262-71. doi: 10.7150/thno.13502. eCollection 2016. Theranostics. 2016. PMID: 26877784 Free PMC article.

3

Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT.

Sandberg D, Tolmachev V, Velikyan I, Olofsson H, Wennborg A, Feldwisch J, Carlsson J, Lindman H, Sörensen J. Sandberg D, et al. Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1337-1346. doi: 10.1007/s00259-017-3650-3. Epub 2017 Mar 6. Eur J Nucl Med Mol Imaging. 2017. PMID: 28261749 Free PMC article.

4

Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold.

Ahlgren S, Orlova A, Wållberg H, Hansson M, Sandström M, Lewsley R, Wennborg A, Abrahmsén L, Tolmachev V, Feldwisch J. Ahlgren S, et al. J Nucl Med. 2010 Jul;51(7):1131-8. doi: 10.2967/jnumed.109.073346. Epub 2010 Jun 16. J Nucl Med. 2010. PMID: 20554729 Free article.

5

Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients.

Sandström M, Lindskog K, Velikyan I, Wennborg A, Feldwisch J, Sandberg D, Tolmachev V, Orlova A, Sörensen J, Carlsson J, Lindman H, Lubberink M. Sandström M, et al. J Nucl Med. 2016 Jun;57(6):867-71. doi: 10.2967/jnumed.115.169342. Epub 2016 Feb 9. J Nucl Med. 2016. PMID: 26912439 Free article.

6

Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules.

Baum RP, Prasad V, Müller D, Schuchardt C, Orlova A, Wennborg A, Tolmachev V, Feldwisch J. Baum RP, et al. J Nucl Med. 2010 Jun;51(6):892-7. doi: 10.2967/jnumed.109.073239. Epub 2010 May 19. J Nucl Med. 2010. PMID: 20484419 Free article.

7

Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.

Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C, Vanhoeij M, Duhoux FP, Gevaert T, Simon P, Schallier D, Fontaine C, Vaneycken I, Vanhove C, De Greve J, Lamote J, Caveliers V, Lahoutte T. Keyaerts M, et al. J Nucl Med. 2016 Jan;57(1):27-33. doi: 10.2967/jnumed.115.162024. Epub 2015 Oct 8. J Nucl Med. 2016. PMID: 26449837 Free article. Clinical Trial.

8

Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody.

Malmberg J, Sandström M, Wester K, Tolmachev V, Orlova A. Malmberg J, et al. Nucl Med Biol. 2011 Nov;38(8):1093-102. doi: 10.1016/j.nucmedbio.2011.04.005. Epub 2011 Jun 22. Nucl Med Biol. 2011. PMID: 22137850

9

First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using ⁸⁹Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer.

Ulaner GA, Lyashchenko SK, Riedl C, Ruan S, Zanzonico PB, Lake D, Jhaveri K, Zeglis B, Lewis JS, O'Donoghue JA. Ulaner GA, et al. J Nucl Med. 2018 Jun;59(6):900-906. doi: 10.2967/jnumed.117.202010. Epub 2017 Nov 16. J Nucl Med. 2018. PMID: 29146695 Free PMC article. Clinical Trial.

10

Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.

Orlova A, Jonsson A, Rosik D, Lundqvist H, Lindborg M, Abrahmsen L, Ekblad C, Frejd FY, Tolmachev V. Orlova A, et al. J Nucl Med. 2013 Jun;54(6):961-8. doi: 10.2967/jnumed.112.110700. Epub 2013 Mar 25. J Nucl Med. 2013. PMID: 23528382 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

173 results

Results by year